TO THE EDITOR: To investigate the impact of maternal diabetes on oocyte metabolism and meiotic maturation, Ratchford et al. (10) reported changes in 3-hydroxyacyl-CoA dehydrogenase II (Hadh2) activity in oocytes after treatment with 5-aminoimidazole-4-carboxamide-1-␤-D-ribofuranoside or after administration of human chorionic gonadotropin, respectively (as shown in Figs. 3A and 4A of Ref. 10). These data were obtained by performing ␤-hydroxyacyl-CoA dehydrogenase (BOAC) assays (6), in which acetoacetyl-CoA served as the substrate. Using this substrate, these authors actually measured the combined activities of Hadh2 and 3-hydroxyacyl-CoA dehydrogenase in the oocytes, since the reduction of acetoacetyl-CoA by NADH could be effectively catalyzed by both of these distinct dehydrogenases (3, 4, 12) .
